ABEONA THERAPEUTICS INC. Additional Paid in Capital, Common Stock
ABEONA THERAPEUTICS INC. (ABEO) had Additional Paid in Capital, Common Stock of $7.00 million as of 2022-12-31, per its 10-K filed 2023-03-29.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent › Additional Paid in Capital
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-13
- 2022-12-31: Additional Paid in Capital, Common Stock $7.00M.
- 2021-12-31: Additional Paid in Capital, Common Stock $7.00M; Additional Paid in Capital, Common Stock as first filed $705.57M.
- 2021-12-21: Additional Paid in Capital, Common Stock $7.00M.
- 2021-09-30: Additional Paid in Capital, Common Stock $687.69M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2022-12-31 | $7.00M 10-K · filed 2023-03-29 | |
| 2021-12-31 | $7.00M 10-K · filed 2024-03-18 | $705.57M 10-K · filed 2022-03-31 |
| 2021-12-21 | $7.00M 10-Q · filed 2026-08-13 | |
| 2021-09-30 | $687.69M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $684.99M 10-Q · filed 2021-07-28 | |
| 2021-03-31 | $680.10M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $672.30M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $669.13M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $667.71M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $665.78M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $664.06M 10-K · filed 2021-03-24 | |
| 2019-09-30 | $565.58M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $559.34M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $546.06M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $543.75M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $542.48M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $536.73M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $533.32M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $529.42M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $440.81M 10-Q · filed 2017-11-14 | |
| 2017-06-30 | $434.67M 10-Q · filed 2017-08-14 | |
| 2017-03-31 | $433.02M 10-Q · filed 2017-05-15 | |
| 2016-12-31 | $431.17M 10-K · filed 2018-03-16 | |
| 2016-09-30 | $388.62M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $384.00M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $381.48M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | $377.99M 10-K · filed 2017-03-30 | |
| 2015-09-30 | $381.01M 10-Q · filed 2015-11-16 | |
| 2014-12-31 | $300.69M 10-Q · filed 2015-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |